Progressive Glioblastoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2026-04-21
Clinical Trial Update: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma [Phase 2]
A Phase 2 trial evaluating relatlimab (anti-LAG-3) plus nivolumab (anti-PD-1) versus lomustine for recurrent glioblastoma has been suspended…